Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     

NOVOCURE LIMITED

(NVCR)
  Report
Real-time Estimate Cboe BZX  -  02:20 2022-09-26 pm EDT
74.12 USD   +1.22%
09/21Novocure Announces Creation of U.S. CNS Cancers Franchise Intended to Renew Focus on Growth in Glioblastoma Business
BU
09/19Insider Sell: Novocure
MT
09/12Insider Sell: Novocure
MT
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

NovoCure: Q2 Earnings Snapshot

07/28/2022 | 07:20am EDT

ST. HELIER, Jersey (AP) _ NovoCure Ltd. (NVCR) on Thursday reported a loss of $24 million in its second quarter.

The St. Helier, Jersey-based company said it had a loss of 23 cents per share.

The results fell short of Wall Street expectations. The average estimate of five analysts surveyed by Zacks Investment Research was for a loss of 14 cents per share.

The oncology drug developer posted revenue of $140.9 million in the period, topping Street forecasts. Five analysts surveyed by Zacks expected $134.9 million.

This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on NVCR at https://www.zacks.com/ap/NVCR

Copyright by Automated Insights, Inc. All rights reserved., source Associated Press News

All news about NOVOCURE LIMITED
09/21Novocure Announces Creation of U.S. CNS Cancers Franchise Intended to Renew Focus on Gr..
BU
09/19Insider Sell: Novocure
MT
09/12Insider Sell: Novocure
MT
09/07Insider Sell: Novocure
MT
09/07Transcript : NovoCure Limited Presents at 2022 Wells Fargo Healthcare Confere..
CI
09/06Insider Sell: Novocure
MT
08/31Novocure to Participate in Upcoming Investor Conferences
BU
08/10Novocure Hosts U.S. Sen. Maggie Hassan at Company's Portsmouth Facility
BU
08/04Insider Sell: Novocure
MT
07/29Truist Securities Drops NovoCure's Price Target to $105 From $118, Keeps Buy Rating
MT
More news
Analyst Recommendations on NOVOCURE LIMITED
More recommendations
Financials (USD)
Sales 2022 547 M - -
Net income 2022 -86,5 M - -
Net Debt 2022 113 M - -
P/E ratio 2022 -93,6x
Yield 2022 -
Capitalization 7 669 M 7 669 M -
EV / Sales 2022 14,2x
EV / Sales 2023 13,4x
Nbr of Employees 1 167
Free-Float 86,8%
Chart NOVOCURE LIMITED
Duration : Period :
NovoCure Limited Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends NOVOCURE LIMITED
Short TermMid-TermLong Term
TrendsBearishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 8
Last Close Price 73,22 $
Average target price 94,25 $
Spread / Average Target 28,7%
EPS Revisions
Managers and Directors
Asaf Danziger Chief Executive Officer & Director
Ashley Cordova Chief Financial Officer
William F. Doyle Executive Chairman
Uri Weinberg Chief Science Officer
Ely Benaim Chief Medical Officer
Sector and Competitors
1st jan.Capi. (M$)
NOVOCURE LIMITED-2.48%7 669
SHOCKWAVE MEDICAL, INC.41.36%9 057
MASIMO CORPORATION-51.40%7 474
PENUMBRA, INC.-35.63%7 007
ASAHI INTECC CO., LTD.-6.56%4 379
GETINGE AB-54.26%4 374